http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
-
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
-
G1 Therapeutics (GTHX) to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis
-
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
-
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
-
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
G1 Therapeutics (GTHX) Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
-
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
-
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
-
G1 Therapeutics (GTHX) Reports Data Showing Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with ES-SCLC
-
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
-
G1 Therapeutics' (GTHX) COSELA Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology
-
G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
-
G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023
-
G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
-
G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
-
G1 Therapeutics to Participate in Two August Investor Conferences
-
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
-
G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel
-
New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer
-
G1 Therapeutics (GTHX) Reports New Results from Phase 2 Trial Confirm Benefit of Trilaciclib
-
New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)
-
G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
-
G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
-
G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
-
G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
-
G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
-
G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023
-
G1 Therapeutics (GTHX) Reports Top Line Results from Phase 3 Trial of Trilaciclib
-
G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE
-
First Prescription for COSELA® (trilaciclib) Issued in China
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference
-
G1 Therapeutics (GTHX) Announces Upcoming 2023 Readouts from Phase 2 and Phase 3 Trials of Trilaciclib
-
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
-
G1 Therapeutics (GTHX) provides initial update on PRESERVE 3
-
G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023
-
G1 Therapeutics to Participate in the 41st Annual J.P. Morgan Conference
-
Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment
